Obesity

NICE CG189 Obesity: identification, assessment and management of overweight and obesity in children, young people and adults
Nov 2014

MHRA Drug Safety Update - Orlistat: theoretical interaction with antiretroviral HIV medicines - information found via this link

Refer to NICE guidance Obesity – working with local communities PH42 November 2012

European Medicines Agency confirms positive benefit-risk balance of orlistat-containing medicines
Existing information on potential very rare liver-related side effects to be harmonised
Finalising its review on orlistat-containing medicines and the possible risk of severe liver injuries, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefit of these medicines continue to outweigh their risks in the treatment of obese or overweight patients with a body mass index of 28 kg/m2 or above. The Committee recommended that the product information for these products should be harmonised to ensure that the information on possible very rare liver-related side effects is the same for all orlistat-containing medicines.